Alzheimer's - Dementia, Author Interviews, Eli Lilly, NEJM / 16.03.2021

MedicalResearch.com Interview with: Stephen Salloway, M.D., M.S. Director of Neurology and the Memory and Aging Program, Butler Hospital Martin M. Zucker Professor of Psychiatry and Human Behavior Professor of Neurology, Alpert Medical School of Brown University Providence, RI 02906  MedicalResearch.com: What is the background for this study? Response: This 78 week phase 2 study tested donanemab in patients with early Alzheimer’s disease. Donanemab is a an anti-amyloid monoclonal antibody that targets the N3 pyroglutamate epitope.  MedicalResearch.com: What are the main findings? Response: The drug produced a substantial lowering of amyloid plaques and showed a slowing in cognitive decline. Key innovations included using PET scans to ensure all patients were amyloid positive and had a moderate level of tau build-up and switching from drug to placebo once the amyloid level was below the expected cut-off for Alzheimer’s disease. There were no new safety signals. The main side-effect was amyloid-related imaging abnormalities (ARIA) that have been seen with other anti-amyloid treatments. ARIA is managed with regular safety MRI scans.  Donanemab is now being tested in a larger phase 3 trial that could lead to regulatory approval. (more…)
Author Interviews, Autism, JAMA, Mental Health Research, Pediatrics, Race/Ethnic Diversity / 08.03.2021

MedicalResearch.com Interview with: Dr. Kevin Lu PhD Clinical Pharmacy and Outcomes Sciences College of Pharmacy Medical University of South Carolina MedicalResearch.com: What is the background for this study?  Response: It is documented that the prevalence of autism spectrum disorder (ASD) has been increasing in the past few years. However, no information on potential racial and ethnic disparities in ASD diagnosis can be found in the literature. Most recently, the possible structural racism and health inequities have been a concern for the public and policy makers. (more…)
Alzheimer's - Dementia, Author Interviews, UCSD / 03.03.2021

MedicalResearch.com Interview with: Dr. Steven L. Wagner PhD University of California, San Diego Department of Neurosciences Professor in Residence School of Medicine, Medical Teaching Facility Room 150 La Jolla, California 92093-0624  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Amyloid plaques are pathological hallmarks of Alzheimer’s disease (AD)—clumps of misfolded proteins that accumulate in the brain, disrupting and killing neurons and resulting in the progressive cognitive impairment that is characteristic of the widespread neurological disorder.  Amyloid plaques are composed of small protein fragments called amyloid beta (Aβ) peptides. These peptides are generated by enzymes called β-secretase and γ-secretase, which sequentially cleave a protein called amyloid precursor protein on the surfaces of neurons to release Aβ fragments of varying lengths. Some of these fragments, such as Aβ42, are particularly prone to forming plaques, and their production is elevated in patients with mutations predisposing them to early-onset AD. Several attempts have been made to treat or prevent AD using drugs that inhibit either β-secretase or γ-secretase, but many of these drugs have proved to be highly toxic or unsafe in humans, likely because β-secretase and γ-secretase are required to cleave additional proteins in the brain and other organs. Instead, Wagner and colleagues investigated the therapeutic potential of drugs known as γ-secretase modulators or GSMs, which instead of inhibiting the γ-secretase enzyme, slightly alter its activity so that it produces fewer Aβ peptides that are prone to form plaques while continuing to duties cleaving other protein targets. “GSMs offer the ability to mitigate mechanism-based toxicities associated with γ-secretase inhibitors,” said Wagner.  (more…)
Education, Mental Health Research / 23.02.2021

Perhaps you are considering a career change or want to take the next steps in your counseling career journey. A masters in mental health counseling online could be the perfect way to help you achieve these goals. Becoming a mental health counselor is a very rewarding yet demanding job, and you will need many different skills, both technical and personal, in order to succeed. If you love working with and helping people, becoming a mental health counselor may be the perfect career choice for you. Here are a couple of basics about studying online for a masters in mental health counseling. What is a masters in mental health counseling online degree? Undertaking a masters in mental health counseling online can help you on your journey to becoming a fully licensed mental health counselor. It is a masters degree that is taught through a mixture of in-person fieldwork and online course work. A masters in mental health counseling online prepares you for the various licensing exams you will need to take in order to progress into the next stage of your career. The majority of positions and jobs within mental health counseling require a masters as a minimum, so a masters in mental health counseling online is a great first step in pursuing this career path. (more…)
Author Interviews, Brain Injury, Exercise - Fitness, Gender Differences, Pediatrics, University of Pennsylvania / 30.01.2021

MedicalResearch.com Interview with: Christina L. Master, MD, FAAP, CAQSM, FACSM Professor of Clinical Pediatrics Perelman School of Medicine at the University of Pennsylvania Co-Director, Minds Matter Concussion Program Pediatric and Adolescent Sports Medicine, Division of Pediatric Orthopedics Attending Physician, Care Network - Karabots Center The Children's Hospital of Philadelphia Philadelphia, PA 19104 MedicalResearch.com: What is the background for this study? Response: There have been multiple studies investigating potential sex differences in outcomes from concussion which have sometimes had conflicting results with some studies indicating that females take longer to recover than males and some studies reporting no difference in recovery between females and males, with most of these studies being conducted either retrospectively or prospectively in smaller cohorts. This large-scale multi-center prospective study in collegiate athletes provided an opportunity to compare females and males across comparable sports to examine both potential intrinsic or biologic factors (sex differences) or extrinsic (environmental or gender differences) that contribute to outcomes. (more…)
Alzheimer's - Dementia, Author Interviews, Cognitive Issues, Memory, Surgical Research / 23.01.2021

MedicalResearch.com Interview with: Pascual Sánchez-Juan, MD, PhD Servicio de Neurología Hospital Universitario "Marqués de Valdecilla" Unidad de Deterioro Cognitivo https://www.facebook.com/deteriorocognitivovaldecilla Director científico Biobanco Valdecilla Avda Marqués de Valdecilla s/n  MedicalResearch.com: What is the background for this study? Response: Alzheimer's disease is one of the greatest public health challenges. From the moment the first lesions appear in the brain to the clinical manifestations, up to 20 years can pass. Today we can detect the presence of these initial lesions through biochemical markers such as amyloid-β, which is one of the main proteins accumulated in the brains of Alzheimer's patients. The prevalence of cerebral amyloid-β pathology in cognitively asymptomatic individuals increases with age. It has been estimated that 21.1% of the population at the age of 65 will have a positive amyloid scan or a pathological cerebrospinal fluid (CSF) amyloid-β determination, and which will double by the age of 90. Due to the aging of our societies and advances made in medical care, an increasing number of elderly and more fragile people are considered candidates for major surgery. In preoperative screenings, respiratory and cardiovascular functions are routinely checked; however, it is not commonly assessed how the brain is going to cope with the intervention. In the clinic, the patient’s relatives frequently tell us that the memory problems began after a surgical procedure or a hospital admission. This posed us the following question: is this just a recall bias or has surgery triggered the appearance of the symptoms in a previously affected brain?” (more…)
Author Interviews, COVID -19 Coronavirus, Mental Health Research, Race/Ethnic Diversity, Social Issues, UCSF / 15.01.2021

MedicalResearch.com Interview with: Jason Nagata, MD, MSc Assistant Professor of Pediatrics University of California, San Francisco San Francisco, California MedicalResearch.com: What is the background for this study? Response: Food insecurity is the inability to afford or access nutritionally adequate and safe foods for an active, healthy lifestyle. Rates of food insecurity were projected to rise during the COVID-19 pandemic; however, prior studies had not examined the association between food insufficiency, the most extreme form of food insecurity, and mental health. MedicalResearch.com: What are the main findings? Response: Using a large national sample of nearly 64,000 adults, we found that food insufficiency rose from 8.1% to 10.0% during the pandemic. People of color and younger adults had higher risk of food insufficiency. People living in poverty or experiencing recent job loss were at higher risk of food insufficiency. Food insufficiency was associated with symptoms of anxiety, worrying, and depression. Hunger, exhaustion, and worrying about not getting enough food to eat may worsen depression and anxiety symptoms. Receiving food assistance alleviated the relationship between food insufficiency and poor mental health.   (more…)
Author Interviews, Autism, Fertility, Genetic Research / 12.01.2021

MedicalResearch.com Interview with: Michael Skinner,  PhD Eastlick Distinguished Professor Founding Director, Center for Reproductive Biology School of Biological Sciences Washington State University Pullman WA MedicalResearch.com: What is the background for this study? Response: Over twenty years ago we identified the existence of a non-genetic form of inheritance through analysis of environmentally induced epigenetic transgenerational inheritance of disease, now well established in a number of species including humans.  I was giving a talk on this topic at a meeting in Spain.   This study was initiated following the scientific meeting in Spain with an in vitro fertilization clinical group that said they had access to sperm from males with and without autistic children.  It took several years to collect and characterize the samples, and find financial support for the study.  Once this was done then we did the molecular analysis to see if the sperm from fathers with autistic children had epigenetic, DNA methylation alterations, that associated with them having offspring with autism. (more…)
Author Interviews, Brain Injury, Brigham & Women's - Harvard / 03.01.2021

MedicalResearch.com Interview with: Nitin Joshi, Ph.D. Engineering in Medicine/Department of Medicine Brigham and Women's Hospital   Dr. Jeffrey M Karp Ph.D Principal Investigator Professor of Medicine at Brigham and Women’s Hospital Harvard Medical School MedicalResearch.com: What is the background for this study? Would you explain what is meant by the blood brain barrier? How will nanoparticles facilitate transport of drugs into the brain? Response: Over the past few decades, researchers have identified promising therapeutic agents that can target the biological pathways involved in brain diseases. Unfortunately, clinical translation of these therapeutics is limited by their inability to cross the blood brain barrier (BBB) and enter the brain at therapeutically effective levels. The BBB is a highly selective semipermeable border of cells that prevents molecules in the circulating blood from non-selectively crossing into the brain tissue. We have developed a simple targeted nanoparticle platform that can stably encapsulate therapeutic agents and enable their therapeutically effective delivery into the brain. In this work, we have demonstrated the utility of this platform for the treatment of traumatic brain injury (TBI), which is a leading cause of death and disability in children and young adults, with millions of people suffering TBI each year in accidents, sports, and military conflicts. Following primary injury, which is a result of the mechanical impact to the brain, secondary injury gradually occurs over months to years and can lead to neurological dysfunctions, including Alzheimer’s and Parkinson’s diseases. After TBI, the BBB is physically breached for a short time and previous approaches to achieve therapeutically effective transport of drugs across the BBB have been severely limited to utilizing this very short window. However, the extent to which the BBB is physically breached in TBI varies greatly across the patient population. Therefore, current approaches are applicable to only a subset of injuries with substantially breached BBB. Moreover, BBB can self-repair within a few hours to weeks post-injury to restore its integrity. Hence, physical breaching of BBB offers a limited window for therapeutic interventions, which is not ideal as the secondary injury can last months to years and may require repeated dosing over long term. The nanoparticle platform developed in this work can enable therapeutically effective delivery of drugs into the brain, irrespective of the state of the BBB. We achieved this by precise engineering of the surface properties of nanoparticles, which maximized their transport across the BBB. The therapeutic used in this study was a small interfering RNA (siRNA) molecule designed to inhibit the expression of the tau protein, which is believed to play a key role in neurodegeneration. Poly(lactic-co-glycolic acid), or PLGA, a biodegradable and biocompatible polymer used in several existing products approved by the U.S. Food and Drug Administration was used as the base material for nanoparticles. We systematically engineered and studied the surface properties of the nanoparticles to maximize their penetration across the intact, undamaged BBB in healthy mice. This led to the identification of a unique nanoparticle design that maximized the transport of the encapsulated siRNA across the intact BBB and also significantly improved the uptake by the brain cells.  (more…)
Author Interviews, Cognitive Issues, Hearing Loss, JAMA, Race/Ethnic Diversity / 23.12.2020

MedicalResearch.com Interview with: Ariana M. Stickel, Ph.D. Postdoctoral Scholar Department of Neurosciences University of California, San Diego MedicalResearch.com: What is the background for this study? Response: Latinos are projected to have the largest increase in Alzheimer’s disease and related dementia in the coming years, yet we know so little about important risk factors for dementia amongst Latinos. As there has been too little widespread research on diverse Latinos and dementia until recently, we examined the individual and combined relationships of two important risk factors for dementia --hearing impairment and cardiovascular disease risk--in over 9,000 Latinos 45 – 74 years old. Diverse Latinos participated in the study, including Central Americans, Cubans, Dominicans, Mexicans, Puerto Ricans and South Americans residing in the Bronx, NY; Chicago, IL; Miami, FL and San Diego, CA. It is important to study a wide range of Latinos in order to appropriately reflect the diversity of this population. Each participant underwent extensive cardiovascular and diabetes testing, hearing examinations, and cognitive assessments. (more…)
Author Interviews, Autism, Brigham & Women's - Harvard, Education, Pediatrics / 21.12.2020

MedicalResearch.com Interview with: Andrey Vyshedskiy PhD Boston University, Boston MedicalResearch.com: What is the background of ImagiRation? https://imagiration.com/ Response: ImagiRation is a Boston-based startup with links to MIT, Harvard, and Boston University. ImagiRation has developed a highly innovative adaptive language therapy application for children with autism, Mental Imagery Therapy for Autism (MITA). MedicalResearch.com: How is the Mental Imagery Therapy for Autism program delivered? Response: MITA language therapy is administered by parents at home. MITA application works on all smartphones and tablet devices and is designed for children ages 2 to 12 years. (more…)
Alzheimer's - Dementia, Author Interviews, Cognitive Issues, Genetic Research, Nutrition / 11.12.2020

MedicalResearch.com Interview with: Auriel Willette, PhD Assistant Professor Food Science and Human Nutrition Iowa State University MedicalResearch.com: What is the background for this study? Response: To date, pharmacology therapies done to slow down or halt Alzheimer's disease have been inconclusive. Lifestyle interventions like changes in diet and activity are also mixed but do show some promise. Dietary clinical trials or self-reported diet have tended to focus on groups of foods such as the Mediterranean or MIND diet. To build from this excellent work, we were curious if we could pinpoint specific foods that were correlated with changes in fluid intelligence over time. Fluid intelligence represents our ability to creatively use existing knowledge, working memory, and other components of "thinking flexibly." Further, we tested if these patterns of association differed based on genetic risk. In this case, genetic risk was defined as having a family history of Alzheimer's disease or having 1-2 "bad" copies of the Apolipoprotein E (APOE) gene, which is the strongest genetic risk factor for Alzheimer's disease. (more…)
Aging, Author Interviews, Cognitive Issues / 03.12.2020

MedicalResearch.com Interview with: Susanna Rosi, Ph.D.  Lewis and Ruth Cozen Chair II Professor, Brain and Spinal Injury Center Weill Institute for Neuroscience Kavli Institute of Fundamental Neuroscience Departments of Physical Therapy Rehabilitation Science, Neurological Surgery University of California San Francisco MedicalResearch.com: What is the background for this study? Response: Everybody has experienced a “senior moment” forgetting where the car keys are, or where you put your glasses. These forgetful moments are not always indicative of a disease, but rather can be a consequence of normal aging. Normal aging is associated with decline of cognitive abilities, such as memory, spatial orientation, problem solving and executive functioning. Investigating what changes happen in the brain with age, can help us to understand why these ‘senior moments’ occur. When we understand what causes these moments, we can design therapeutics with the hopes of preventing or reversing them.  With increased life expectancy age-associatedmemory decline becomes a growing concern. We wanted to investigate (i) What causes memory decline with age? (ii) Are there ways to reverse it?  (more…)
Author Interviews, Mental Health Research, Psychological Science / 01.12.2020

MedicalResearch.com Interview with: Gert Martin Hald, PhD Head of Section (Environmental Health), Associate Professor Department of Public Health, University of Copenhagen Copenhagen, Denmark MedicalResearch.com: What is the background for this study? Response: Basically, much of previous research has investigated mental and physical health of divorcees only after extensive separation periods, which is mandatory in most countries before juridical divorce unless infidelity or violence is involved in the divorce. During the time of data collection (2016-2019), Denmark where data was collected did not require separation periods before granting divorce. This means that as a first, we could investigate the mental and physical health of divorcees within days of them filling for divorce and perhaps better and more accurately pick up well-known adverse effects of mental- and physical health states of divorcees at the time of their divorce.   (more…)
Alzheimer's - Dementia, Author Interviews, Medical Imaging, Mental Health Research / 01.12.2020

MedicalResearch.com Interview with: Maria Vittoria Spampinato, MD Neuroradiology Division Director Department of Radiology and Radiological Science Medical University of South Carolina Charleston, SC 29425-3230 MedicalResearch.com: What is the background for this study? What are the main findings? Response: Alzheimer’s disease (AD) represents a major public health crisis worldwide. More than 5 million people currently have AD in the United States. AD is a slowly progressing neurodegenerative brain disorder with a long preclinical phase. Many people with AD first suffer from mild cognitive impairment (MCI), a decline in cognitive abilities like memory and thinking skills that is greater than that associated with normal aging. A person with MCI is at an increased risk of developing AD or another dementia, although some individuals with MCI remain cognitively stable or improve. Anxiety is frequently observed in individuals with MCI. The reported prevalence of anxiety in MCI patients varies between 10 and 50%.  In this study we evaluated a cohort of 339 individuals with MCI participating in the Alzheimer’s Disease Neuroimaging Initiative study (ADNI2). During the five years of study participation, 72 patients experienced cognitive decline and were diagnosed with AD. We did not find difference in age, gender and education among patients with and without AD conversion. Patients who progressed had greater atrophy of the hippocampi and entorhinal cortex on their MRI scan, as expected (hippocampal atrophy is often used as a marker of neurodegeneration in AD), as well as greater prevalence of APOE4 is the strongest known genetic risk factor for AD.   Patients who progressed to Alzheimer’s disease also had greater severity of anxiety during the study, as measured using the Neuropsychiatric Inventory-Questionnaire. Next we determined the effect of the MRI findings (hippocampal and entorhinal cortex atrophy), of the genetic risk factor (APOE4) and of the severity of anxiety on the time to progression to AD. We found that higher levels of anxiety were associated with faster progression from MCI to AD, independently of whether they had a genetic risk factor for Alzheimer’s disease or brain volume loss. We still need to understand better the association between anxiety disorders and cognitive decline. We do not know whether increased levels of anxiety are a consequence of cognitive decline or if anxiety exacerbates to cognitive decline. If we were able to find in the future that anxiety is actually contributing to cognitive decline, then we should more aggressively screen for anxiety disorders in the elderly population.  (more…)
Alzheimer's - Dementia, Author Interviews, Lipids, Mental Health Research, Microbiome / 18.11.2020

MedicalResearch.com Interview with: Moira Marizzoni, PhD Researcher, Fatebenefratelli Center in Brescia  MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease is the most common cause of dementia. Still incurable, it directly affects nearly one million people in Europe, and indirectly millions of family members as well as society as a whole. The gut microbiota could play a role in brain diseases including Alzheimer’s disease. Some gut bacteria components or products can reach the brain via the blood and might promote brain amyloidosis (one of the main pathological features in Alzheimer’s disease).   MedicalResearch.com: What are the main findings?  Response: This study evaluated a cohort of 89 people between 65 and 85 years of age composed of subjects suffering from Alzheimer’s disease or other neurodegenerative diseases causing similar memory problems, and of subjects with no memory problems. The study revealed that elevated levels of microbiota-products with known pro-inflammatory properties (i.e. lipopolysaccharides and the short chain fatty acids acetate and valerate) were associated with greater cerebral amyloid pathology while elevated levels of those with anti-inflammatory properties (i.e. the short chain fatty acid butyrate) were associated with lower amyloid pathology. (more…)
Author Interviews, Brain Injury, Exercise - Fitness, JAMA / 17.11.2020

MedicalResearch.com Interview with: Tara L Sharma DO Clinical Assistant Professor of Neurology at UWMC Seattle, WA 98133 MedicalResearch.com: What is the background for this study? What are the main findings? Response: Flying can lead to reduced oxygen partial pressures and cerebral blood flow causing worsening clinical outcome in cases of moderate to severe TBI; however, not much is known regarding the clinical consequences of flying in individuals with concussion or mild TBI. Because many athletes suffer concussions during games, it is necessary to know if flying afterward may potentially hinder their ability to return to play. Overall, we found no associated between air travel and increased symptom severity in both our entire cohort and the subset of football players. (more…)
Author Interviews, Brigham & Women's - Harvard, Dermatology, JAMA, McGill, Mental Health Research / 17.11.2020

Editor's note: This piece discusses suicide. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255.  MedicalResearch.com Interview with: David-Dan Nguyen, MPH Research Fellow | Center for Surgery and Public Health, Brigham and Women's Hospital Medical Student | McGill University MedicalResearch.com: What is the background for this study? Response: There is ongoing concern about the side-effects of finasteride, a drug used for the management of alopecia and benign prostatic hyperplasia. These concerns have led to the coining of the “post-finasteride syndrome” which remains controversial. Indeed, there is conflicting evidence on the post-finasteride syndrome/adverse events associated with finasteride. We wanted to contribute to this conflicting body of evidence by examining suicidality, depression, and anxiety reports linked to finasteride use using the WHO’s pharmacovigilance database, VigiBase. Such pharmacovigilance databases are useful for the study of rare adverse events that are suspected to be associated with medication use. (more…)
Author Interviews, COVID -19 Coronavirus, Depression, Mental Health Research, Occupational Health, Pediatrics, UCSF / 11.11.2020

MedicalResearch.com Interview with: Kyle T. Ganson, PhD, MSW Assistant Professor, Factor-Inwentash Faculty of Social Work University of Toronto Toronto, Canada   Jason Nagata, MD, MSc Assistant Professor of Pediatrics University of California, San Francisco San Francisco, California, USA     MedicalResearch.com: What is the background for this study? Response: A quarter of young adults in the US have reported being unemployed during the COVID-19 pandemic. Young adults may be especially affected by employment loss as they often work in industries most adversely affected by social distancing. MedicalResearch.com: What are the main findings? Response: Among a sample of nearly 5,000 young adults age 18 to 26 in the US, we found that since March 2020, young adults who lost their job or were part of a household that experienced employment loss were more likely than those with secure employment to experience four common symptoms of anxiety and depression. This was also true of young adults who expected an employment loss in the next four weeks. The study also found that symptoms of anxiety and depression were common among the sample of young adults. In the seven days prior to the survey, 75% reported being nervous, anxious or on edge, 68% reported not being able to stop or control worrying, 67% reported having little interest or pleasure in doing things, and 64% reported feeling down, depressed, or hopeless. (more…)
Author Interviews, Cognitive Issues, Emory, Exercise - Fitness, Heart Disease / 27.10.2020

MedicalResearch.com Interview with: Henry Mahncke, PhD Chief Executive Officer Posit Science https://www.brainhq.com/?v4=true&fr=yDr. Mahncke earned his PhD at UCSF in the lab where lifelong brain plasticity was discovered. At the request of his academic mentor, he currently leads a global team of more than 400 brain scientists engaged in designing, testing, refining, and validating the computerized brain exercises found in the BrainHQ app from Posit Science, where he serves as CEO. MedicalResearch.com Tell us what’s important about this new study in people with heart failure? Response: Heart failure is a common condition that even when properly treated can have adverse long-term health outcomes and high medical costs. Heart failure commonly causes cognitive impairment, which can have devastating effect on patient abilities to engage in self-care, and which contributes to poor clinical outcomes, increased rehospitalizations, and higher mortality rates. What makes these results exciting is that the Emory University researchers discovered that a simple intervention – a fairly modest amount of walking and brain exercise – not only significantly improved a standard measure of cognition, but also significantly improved multiple measures that drive better health outcomes and lower costs. MedicalResearch.com: What is heart failure? Response: Heart failure – sometimes called congestive heart failure or congestive cardiac failure – is when the heart cannot pump sufficient blood flow to maintain the body’s needs. Common symptoms include excessive tiredness, shortness of breath and swelling particularly in legs. It’s treated with a combination of lifestyle changes, drugs, and devices. An estimated 6.5 million Americans are diagnosed with heart failure, with 960,000 new cases each year, leading some to describe it as reaching epidemic proportions. In older adults, it’s the most common cause of hospital readmissions within 30 days of discharge and among the most costly areas of Medicare expenditures. (more…)
Author Interviews, Depression, Mental Health Research, Nature, PTSD / 21.10.2020

MedicalResearch.com Interview with: Amit Etkin, MD, PhD Department of Psychiatry and Behavioral Sciences Wu Tsai Neurosciences Institute, Stanford Universitu Stanford, CA    MedicalResearch.com: What is the mission of Cohen Veterans Bioscience - CVB?  Cohen Veterans Bioscience Response: Cohen Veterans Bioscience (CVB) is a non-profit 501(c)(3) research biotech dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of Veterans and civilians who suffer the devastating effects of trauma-related and other brain disorders. To learn about CVB’s research efforts visit www.cohenveteransbioscience.org.   MedicalResearch.com: How can patients with PTSD or MDD benefit from this information? Response: With the discovery of this new brain imaging biomarker, patients who suffer from PTSD or MDD may be guided towards the most effective treatment without waiting months and months to find a treatment that may work for them.   MedicalResearch.com: What is the background for this study? Response: This study, which was supported with a grant from Cohen Veterans Bioscience, grants from the National Institute of Mental Health (NIMH and other supporters, derives from our work over the past few years which has pointed to the critical importance of understanding how patients with a variety of psychiatric disorders differ biologically. The shortcomings of our current diagnostic system have become very clear over the past 1-2 decades, but the availability of tools for transcending these limitations on the back of objective biological tests has not kept pace with the need for those tools. In prior work, we have used a variety of methods, including different types of brain imaging, to identify brain signals that underpin key biological differences within and across traditional psychiatric diagnoses. We have also developed specialized AI tools for decoding complex patterns of brain activity in order to understand and quantify biological heterogeneity in individual patients. These developments have then, in turn, converged with the completion of a number of large brain imaging-coupled clinical trials, which have provided a scale of these types of data not previously available in the field. (more…)
COVID -19 Coronavirus, Mental Health Research / 14.10.2020

Around 8% of the population in America experiences sleep bruxism - a disorder characterized by teeth grinding and jaw clenching that leads to headaches, the wearing stress-pandemic-bruxism-covid-19down of teeth, and jaw pain - to mention just a few effects. A new market research report called COVID-19 Impact on Sleeping Bruxism Treatment Market Overview and Forecast 2020 to 2026 has found that the current health crisis has led to a spike in bruxism. The report forecasts a big rise in the need for treatment of the effects of bruxism owing to currently high levels of stress across the globe.

Why Is Bruxism On The Rise?

It is a stressful time in many ways, and this increases the likelihood of teeth grinding and jaw clenching at night. A study published in the journal Head & Face Medicine showed that nightly gnashing of teeth was especially prevalent among those who tried to cope with stress by escaping from difficult situations. Bruxism can lead to everything from tooth sensitivity to pain in the muscles of the jaw responsible for chewing. While there are many exercises to soothe tight jaw muscles, this is just one approach that should be considered. Because bruxism can actually lead to tooth loss, it should be taken seriously, and if stress is the cause, then this separate issue should also be tackled proactively.

(more…)

Author Interviews, Education, Memory, Pediatrics / 08.10.2020

MedicalResearch.com Interview with: Leonie Margarita Kausel, PhD Postdoctoral Researcher Development University Santiago, Chile  MedicalResearch.com: What is the background for this study? Response: As a violin teacher, I observed the positive impact on many levels that musical training has on children and as a scientist (Biochemist), I was intrigued to be able to show this with data. I thought this was very important, because in my experience childhood music education can give you so much joy and important skills for life, but it is often not considered to be important in educational settings. After attending a seminar on education and neuroscience, I discovered that this discipline could allow me to investigate this in a scientific manner. This inspired me to enter the Neuroscience PhD program at the Pontificia Universidad Católica de Chile where I was lucky to work with Dr. Francisco Aboitiz, who has vast experience in attention research (ADHD) and is an international expert in language and evolution. At that time Dr. Mary Elizabeth Sutherland was making her postdoc at the lab, and she had worked with Dr. Robert Zatorre, one of the leading researchers in music and the brain. Also, I was lucky to work with Dr. Francisco Zamorano, a pioneer of fMRI research in Chile. So together we designed the research. :)  Also, I am very grateful that I could make a research stay at the Lab of Dr. Gottfried Schalug, who is also a pioneer in the research of music and the brain, and who inspired me to do this research since he wrote the first papers that I read about this subject.  (more…)
Author Interviews, Brain Injury, Brigham & Women's - Harvard, JAMA / 25.09.2020

MedicalResearch.com Interview with: Maria Gabriela Figueiro Longo, MD, MSc Department of Radiology, Massachusetts General Hospital Harvard Medical School, Boston MedicalResearch.com: What is the background for this study? What are the main findings? Response: Transcranial low-level light therapy (3LT) has been shown to be effective in animal models of traumatic brain injury. Our goal was to assess the 3LT in humans with acute TBI. We tested (1) safety, and (2) any effect in the brain in a measurable way. We found positive results for both - there was no event adverse during the trial related to the 3LT; and we found some differences in the brain MRI diffusivity parameters in the patients who received light therapy compared to the sham group. The study was not powered for clinical evaluation, although there was a trend towards lower symptom burden in the treated group. (more…)
Author Interviews, Cognitive Issues, JAMA, Sleep Disorders / 21.09.2020

MedicalResearch.com Interview with: Wuxiang Xie, PhD Peking University Clinical Research Institute Peking University First Hospital Beijing, China MedicalResearch.com: What is the background for this study? Response: Dementia is one of the most common and serious disorders in later life. A strong relationship between sleep and cognitive function had been previously reported, while the relationship between sleep duration and the trajectory of cognitive decline remains unclear.  (more…)
Addiction, Author Interviews, Cleveland Clinic, COVID -19 Coronavirus, Mental Health Research / 16.09.2020

MedicalResearch.com Interview with: Rong Xu PhD Center for Artificial Intelligence in Drug Discovery, School of Medicine Case Western Reserve University Cleveland, OH MedicalResearch.com: What is the background for this study? What are the main findings? Response: Chronic use of tobacco, alcohol and other drugs is associated with cardiovascular, pulmonary, and metabolic diseases, all of which are also risk factors for COVID-19 infection and for worse outcomes.  Additionally, individuals with substance use disorders are more likely to experience social adversity such as homelessness, decreased access to health care, housing insecurity among others. Based on these, we hypothesis or predict that individuals with SUD are especially vulnerable for COVID-19 infection and adverse outcomes. In our study, we found that  individuals with substance use disorders, especially individuals with OUD and African Americans with SUD, as having increased risk for COVID-19 and its adverse outcomes  (more…)
Author Interviews, Brain Injury, JAMA / 16.09.2020

MedicalResearch.com Interview with: Susan Rowell MD, MBA, MCR Associate Professor, Department of Surgery Division of Trauma, Acute & Critical Care Surgery Duke University School of Medicine Durham, NC 27710 MedicalResearch.com: What is the background for this study? Response: Tranexamic acid (TXA) has been increasingly used in trauma patients since publication of the CRASH-2 trial in 2010 demonstrated a survival benefit for patients at risk for traumatic hemorrhage. Subsequently, it was shown that the earlier TXA was administered, the better the outcome. There had been several small studies suggesting that TXA may also be beneficial in patients with traumatic brain injury (TBI), however, an adequate prospective randomized trial was needed. In this trial we randomized over 1000 patients with moderate and severe TBI as early as possible after injury (by paramedics in the prehospital setting an average of 42 minutes after injury) to either a 1-gram TXA bolus followed by a 1-gram 8-hour TXA infusion (the dose typically used for trauma patients), a 2-gram TXA bolus only (a logistically easier route of administration requiring no maintenance infusion), or placebo only. (more…)